What is the terminal elimination half‑life of apixaban?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 6, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Half-Life of Apixaban

The terminal elimination half-life of apixaban is approximately 12 hours following oral administration. 1

Pharmacokinetic Details

The half-life of apixaban shows some variation based on the formulation and patient population:

  • Standard half-life: Approximately 12 hours after oral administration 2, 3, 4, 1
  • Range reported in clinical studies: 8 to 14 hours in healthy men 5
  • Extended range in some populations: 11 to 26.8 hours following tablet doses ≥5 mg 6
  • Consistent findings: Multiple studies confirm approximately 11-12 hours 3, 7, 8

Clinical Implications

Steady-State Achievement

  • With a half-life of ~12 hours, apixaban reaches steady-state levels within 3 days when dosed twice daily 2
  • The accumulation index is 1.7, consistent with twice-daily dosing and the observed elimination half-life 8

Duration of Anticoagulant Effect

  • The pharmacodynamic effect of apixaban can be expected to persist for at least 24 hours after the last dose (approximately two drug half-lives) 1
  • This is clinically relevant when considering timing of procedures or managing bleeding complications 1

Dosing Frequency

  • The 12-hour half-life supports the twice-daily dosing regimen used in clinical practice without need for anticoagulation monitoring 9

Important Caveats

Age-related variation: The elimination half-life may be slightly prolonged in elderly patients, though this does not typically require dose adjustment based on age alone 4, 1

Renal impairment: While the half-life itself is not dramatically altered, overall drug exposure increases with declining renal function, which is why dose adjustments are recommended in patients with severe renal impairment 4, 1

Formulation differences: Earlier studies with solution formulations showed shorter half-lives (3.6-6.8 hours) compared to tablet formulations, likely due to dissolution-limited absorption characteristics 6

Related Questions

How can the effectiveness of apixaban (Eliquis) be assessed in a patient?
Can I switch Eliquis (apixaban) from 5 mg twice daily to a 10 mg once‑daily dose?
How long should apixaban 5 mg twice daily be held before a paracentesis?
What is the washout period for Eliquis (apixaban)?
Does crushing an apixaban tablet for administration through a Ryle’s (nasogastric) tube reduce its potency or affect absorption?
In an 85‑year‑old man with painless hematuria and CT showing an enlarged prostate causing bladder compression but no obstructive uropathy, urothelial lesion, or significant renal pathology (only a 3 mm non‑obstructing left renal stone and simple cysts), what diagnostic work‑up and management should be pursued?
In a 44-year-old male weighing 214–219 lb with blood pressure 115–130/80 mmHg, currently on methylphenidate extended‑release 54 mg once daily and immediate‑release 10 mg twice daily, can the extended‑release dose be increased to 72 mg and the immediate‑release dose reduced to 5 mg twice daily?
A patient with depression and anxiety on sertraline (SSRI) and prazosin has persistent anxiety despite trials of quetiapine (Seroquel), aripiprazole (Abilify), and olanzapine (Zyprexa); what is the next best pharmacologic management?
What is the significance of an elevated white blood cell count of 14.27 ×10⁹/L and how should it be evaluated and managed?
How should elevated iron levels be evaluated and managed?
What is the appropriate evaluation and management for white ulcerating patches on the penis?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.